BiotechTube

NBI-1065890 + Placebo

Phase 2Recruiting
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tardive Dyskinesia

Conditions

Tardive Dyskinesia

Trial Timeline

Jan 1, 2026 → Mar 1, 2027

NCT ID
NCT07365462

About NBI-1065890 + Placebo

NBI-1065890 + Placebo is a phase 2 stage product being developed by Neurocrine Biosciences for Tardive Dyskinesia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07365462. Target conditions include Tardive Dyskinesia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07365462Phase 2Recruiting

Competing Products

13 competing products in Tardive Dyskinesia

See all competitors
ProductCompanyStageHype Score
SarizotanMerckPre-clinical
23
levetiracetam + placeboUCBPhase 3
74
ValbenazineNeurocrine BiosciencesPhase 1
30
Valbenazine Oral CapsuleNeurocrine BiosciencesApproved
82
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
NBI-98854Neurocrine BiosciencesPhase 3
74
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved
82
NBI-98854Neurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 3
74
ValbenazineNeurocrine BiosciencesPhase 3
74
NBI-98854 + NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved
82

Other Products from Neurocrine Biosciences

Valbenazine Oral CapsuleApproved
82
ValbenazineApproved
82
ValbenazineApproved
82
Valbenazine + Placebo oral capsuleApproved
82
Valbenazine + Placebo oral capsuleApproved
82